Company news
Personalis, Inc. (NASDAQ:PSNL) news
Personalis, Inc. news releases on 6ix. Latest, Aug 4, 2026: Personalis Reports Second Quarter Results and Recent Highlights
Press releases & updates
Personalis Reports Second Quarter Results and Recent Highlights
August 4, 2026
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
July 20, 2026
Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain
July 14, 2026
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
June 9, 2026
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
June 2, 2026
Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium
May 26, 2026
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
May 20, 2026
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
May 13, 2026
Personalis Reports First Quarter Results and Recent Highlights
May 7, 2026
Personalis to Announce First Quarter 2026 Financial Results
April 23, 2026
Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026
April 21, 2026
Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026
April 13, 2026
Personalis to Participate in the 25th Annual Needham Virtual Conference
April 1, 2026
Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption
March 16, 2026
Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®
March 11, 2026
Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
February 26, 2026
Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference
February 17, 2026
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results
February 12, 2026
Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance
February 10, 2026
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors
February 1, 2026
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
January 28, 2026
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™
January 11, 2026
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights
January 7, 2026
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors
December 16, 2025
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer
December 10, 2025
Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 17, 2025
Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer
November 9, 2025
Personalis Reports Third Quarter 2025 Financial Results
November 3, 2025
Personalis to Announce Third Quarter 2025 Financial Results
October 20, 2025
Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing
October 15, 2025
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 14, 2025
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
September 9, 2025
Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing
September 2, 2025
Personalis to Participate in Upcoming Investor Conferences
August 26, 2025
Tempus Reports Second Quarter 2025 Results
August 8, 2025
Personalis Reports Second Quarter 2025 Financial Results
August 4, 2025
Personalis to Announce Second Quarter 2025 Financial Results
July 21, 2025
Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients
July 8, 2025
Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
June 2, 2025
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse
June 1, 2025
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
May 21, 2025
Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference
May 13, 2025
Personalis Reports First Quarter 2025 Financial Results
May 5, 2025
Personalis’ NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study
April 27, 2025
Personalis to Announce First Quarter 2025 Financial Results
April 21, 2025
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection
April 21, 2025
Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference
March 25, 2025
New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection
March 2, 2025
Personalis Reports Fourth Quarter and Full Year 2024 Financial Results
February 26, 2025
Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference
February 17, 2025